Jane Street’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.17M | Sell |
124,300
-21,000
| -14% | -$188K | ﹤0.01% | 6197 |
|
|
2026
Q1 | $1.18M | Sell |
145,300
-514,600
| -78% | -$4.66M | ﹤0.01% | 6160 |
|
|
2025
Q4 | $4.43M | Sell |
659,900
-31,800
| -5% | -$240K | ﹤0.01% | 3422 |
|
|
2025
Q3 | $6M | Sell |
691,700
-124,700
| -15% | -$971K | ﹤0.01% | 3157 |
|
|
2025
Q2 | $5.14M | Sell |
816,400
-19,300
| -2% | -$128K | ﹤0.01% | 2956 |
|
|
2025
Q1 | $5.36M | Sell |
835,700
-1,522,400
| -65% | -$12.6M | ﹤0.01% | 2841 |
|
|
2024
Q4 | $19M | Sell |
2,358,100
-347,600
| -13% | -$3.35M | ﹤0.01% | 1298 |
|
|
2024
Q3 | $34.2M | Buy |
2,705,700
+277,400
| +11% | +$3.58M | 0.01% | 887 |
|
|
2024
Q2 | $30.7M | Buy |
2,428,300
+1,432,000
| +144% | +$14.4M | 0.01% | 966 |
|
|
2024
Q1 | $4.76M | Buy |
996,300
+165,800
| +20% | +$769K | ﹤0.01% | 2683 |
|
|
2023
Q4 | $3.99M | Buy |
830,500
+24,000
| +3% | +$147K | ﹤0.01% | 3190 |
|
|
2023
Q3 | $5.84M | Buy |
806,500
+372,800
| +86% | +$2.98M | ﹤0.01% | 2390 |
|
|
2023
Q2 | $3.22M | Sell |
433,700
-20,400
| -4% | -$160K | ﹤0.01% | 3374 |
|
|
2023
Q1 | $3.15M | Sell |
454,100
-215,500
| -32% | -$1.98M | ﹤0.01% | 3074 |
|
|
2022
Q4 | $6.88M | Buy |
669,600
+315,700
| +89% | +$5.57M | ﹤0.01% | 2065 |
|
|
2022
Q3 | $6.44M | Sell |
353,900
-356,800
| -50% | -$15.5M | ﹤0.01% | 2239 |
|
|
2022
Q2 | $36.6M | Sell |
710,700
-184,700
| -21% | -$9.57M | 0.02% | 710 |
|
|
2022
Q1 | $65.9M | Sell |
895,400
-254,200
| -22% | -$22.7M | 0.02% | 557 |
|
|
2021
Q4 | $164M | Buy |
1,149,600
+421,500
| +58% | +$72.4M | 0.05% | 228 |
|
|
2021
Q3 | $151M | Buy |
728,100
+59,800
| +9% | +$13.2M | 0.05% | 240 |
|
|
2021
Q2 | $142M | Buy |
668,300
+308,400
| +86% | +$56.5M | 0.06% | 231 |
|
|
2021
Q1 | $65.3M | Sell |
359,900
-68,800
| -16% | -$13.7M | 0.03% | 400 |
|
|
2020
Q4 | $47.8M | Buy |
428,700
+13,300
| +3% | +$1.41M | 0.02% | 466 |
|
|
2020
Q3 | $45M | Sell |
415,400
-160,400
| -28% | -$19.5M | 0.03% | 427 |
|
|
2020
Q2 | $48M | Buy |
575,800
+510,900
| +787% | +$19.5M | 0.04% | 375 |
|
|
2020
Q1 | $881K | Buy |
+64,900
| New | +$549K | ﹤0.01% | 2950 |
|
|
2016
Q4 | – | Sell |
-5,165
| Closed | -$215K | – | 4435 |
|
|
2016
Q3 | $215K | Buy |
+5,165
| New | +$667K | ﹤0.01% | 3647 |
|
|
2016
Q2 | – | Sell |
-580
| Closed | -$60K | – | 4424 |
|
|
2016
Q1 | $60K | Buy |
+580
| New | +$62.2K | ﹤0.01% | 3941 |
|
Other funds holding NVAX
SCM
S
Jane Street's NVAX Position: Q2 2026 in Review
Jane Street reduced its Novavax (NVAX) stake by 69% in Q2 2026, selling an estimated $399K and leaving 19,663 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #10181.
Jane Street first reported a position in NVAX in Q3 2013 and has held it in 41 quarters since. The position peaked at $93M in Q4 2021. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- Jane Street held 19,663 shares of Novavax worth $185K as of Q2 2026.
- Jane Street sold 44,494 Novavax shares in Q2 2026, an estimated $399K.
- Novavax made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10181 holding.
- Jane Street first reported a position in Novavax in Q3 2013 and has held it in 41 quarters since.
- Jane Street's Novavax position peaked at $93M in Q4 2021.
- 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.